Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other ...

Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, evaluates fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) and its role in breast ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell ...

Analyst Tim Chiang of Capital One Financial assigned a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of ...

In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma ...

A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis ...

Topline interim results were announced from a trial evaluating sibeprenlimab for adults with immunoglobulin A nephropathy.

Researchers at WashU Medicine have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment. Untreated mice develop major scarring ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy—similar to that ...

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...